We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.05 | -33.33% | 0.10 | 10,276,428 | 13:32:11 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.05 | 0.15 | 0.15 | 0.075 | 0.15 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -0.27 | 453.89k |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:02:26 | O | 828,333 | 0.12 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 15/4/2024 | 11:48 | UK RNS | Byotrol PLC Holding(s) in Company |
| 08/4/2024 | 07:00 | UK RNS | Byotrol PLC Holding(s) in Company |
| 03/4/2024 | 10:59 | ALNC |  TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit |
| 02/4/2024 | 15:27 | UK RNS | Byotrol PLC Director Dealing |
| 28/3/2024 | 07:00 | UK RNS | Byotrol PLC Proposed Cancellation |
| 22/12/2023 | 11:44 | UKREG | Byotrol PLC Holding(s) in Company |
| 07/12/2023 | 11:49 | ALNC | Byotrol shares jump as optimistic despite half-year loss widening |
| 07/12/2023 | 07:00 | UKREG | Byotrol PLC Half-year Report |
| 14/11/2023 | 14:21 | ALNC | TRADING UPDATES: Byotrol interim sales flat; Argo loss narrows |
| 14/11/2023 | 07:00 | UKREG | Byotrol PLC Trading Update |
Byotrol (BYOT) Share Charts1 Year Byotrol Chart |
|
1 Month Byotrol Chart |
Intraday Byotrol Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/4/2024 | 21:00 | BYOTROL-CAN DELIVER AMAZING RESULTS | 12,844 |
| 09/8/2022 | 08:34 | TRADING4GOOD FROM LSE | 2 |
| 24/6/2022 | 08:31 | Byot | - |
| 13/4/2020 | 21:14 | Byotrol (BYOT) One to Watch on Wednesday | 2 |
| 27/2/2016 | 19:04 | Byotrol:::::::::Cleaning Up | 45 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-15 15:02:27 | 0.12 | 828,333 | 994.00 | O |
| 2024-04-15 14:27:08 | 0.08 | 4,530 | 3.40 | O |
| 2024-04-15 13:06:41 | 0.08 | 39,577 | 29.72 | O |
| 2024-04-15 12:52:27 | 0.13 | 410,803 | 513.50 | O |
| 2024-04-15 12:31:46 | 0.10 | 1,012,000 | 1,012.00 | O |
| Top Posts |
|---|
Posted at 15/4/2024 09:20 by Byotrol Daily Update Byotrol Plc is listed in the Chemicals & Chem Preps, Nec sector of the London Stock Exchange with ticker BYOT. The last closing price for Byotrol was 0.15p.Byotrol currently has 453,890,405 shares in issue. The market capitalisation of Byotrol is £453,890. Byotrol has a price to earnings ratio (PE ratio) of -0.27. This morning BYOT shares opened at 0.15p |
Posted at 15/4/2024 21:00 by mudbath Medimark ScientificFor a consideration of £4.5million Byotrol envisaged:- "Immediately provides Byotrol with greater scale than could be achieved through current rates of organic growth. Medimark is profitable and cash generative and fits extremely well with Byotrol's existing products and technology. · Expected to be materially earnings enhancing in first year from acquisition. The combination of the two businesses will greatly accelerate Byotrol's growth profile whilst significantly reducing the execution risk from purely organic expansion. · Highly complementary acquisition, offering extensive sales, marketing and distribution expertise in Byotrol's core markets. Specific complementarity with Byotrol's Professional and Petcare businesses with significant synergies expected over time, including:· Enhanced distribution of Byotrol technologies to Medimark customers, in the UK and overseas, boosting economies of scale, distribution and market segment expertise · Highly experienced, well-connected and resilient sales team and sales support · Introduction of stronger disinfectant technologies to Byotrol portfolio including a proprietary sporicidal formulation · Doubles Byotrol workforce, creating immediate critical mass with cost synergies available from bringing Medimark technical work in house. · Medimark is on track to deliver EBITDA of £500k for the full year to March 2019, which will trigger the first earn-out payment · Executive management staying with the combined business for the earnout and beyond, with incentives closely aligned with Byotrol shareholders. Executive management locked-in from share sales for three years from completion." Following the Acquisition, it is expected that Byotrol will have cash balances in excess of £2.5m, providing more than sufficient resource to drive growth of the combined businesses." Add in a subsequent pandemic and one has to seriously question the competence of Byotrol's managegement when current reality includes a possible delisting and yet another upcoming cash call. |
Posted at 12/4/2024 16:07 by sikhthetech 1gw,I see you mentioned SLN. They moved from AIM to a US listing. So people can still easily trade them, whether in ISA or not. That's different from a private company. SLN's share price is still below the price they IPO'ed when they listed in US. Why not also mention Trmr, now Nexn (ex blnx) - a share you and your mates ramped, despite all the red flags. Their discounted placing and IPO was at 800p and their current share price is around 230p, so another disaster. |
Posted at 08/4/2024 11:24 by cliffpeat Any views on possible/probable dilution of current shareholders after delisting (assuming that goes ahead)?"After the capital reorganization, each of the 453,890,405 existing ordinary shares will be subdivided and converted into one new ordinary share of £0.0001 each." With a nominal par value of 1/100th of a penny (£0.0001) it leaves the present directors with the possibility of raising new share capital equal to more than 50% of the post-raise position for as little as £45.4k. If a raise of 453.9m shares was priced at (say) the current "buy" pps of 15/100th of a penny per share, it would raise £681k. Also, I suggest, it's worth looking at the Part II of the RNS "Circular" and you see the Memo & Arts change proposals if it becomes a private company. That puts enormous power in the hands of the directors (particularly if they have a friendly majority shareholder). So how will it unfold? The following is only a guess and certainly not an opinion or slur on the probity of the current directors - one scenario might be: 1. Delist as proposed 2. Raise capital at not much above nominal share price and shift control to the directors and if required a "connected" entity at a price to dilute existing shareholders to 20% or less 3. I doubt that numbers would justify offshoring majority ownership and management - but who knows where the new capital is coming from? 4. Divest Technical R&D team and Seaweed IP to large competitor for £1m or so. 5. Use funds to continue a pared down core trading company producing a profit before tax of £2m+ p.a. (see post 10581) 6. Sell company for an earnings multiple of 3x or more in a couple of years. Just thinking aloud and no clue as to the merits of selling now at almost 100% loss or staying in. DYOR |
Posted at 07/4/2024 16:36 by loafofbread Less than 2 years ago they thought 3.25p was a decent price.35 times more than our current share price Todays price is as artificial as you could get. The second relates to the Convertible Bond. The Group issued a Convertible Bond for GBP1m in July 2022 to new and existing investors in the Company, including Board directors. The Loan Notes have a term of five years, are senior in ranking, unsecured and convertible at investors' option into ordinary shares in the capital of the Company ("Ordinary Shares") at a price of 3.25 pence per Ordinary Share, representing a 30% premium to the mid-price of the Company's share price at close of business on 26 July 2022. The Loan Notes carry a coupon of 9% per annum, payable quarterly in arrears. Based on the issue size of GBP1,000,000, the Loan Notes would, if converted, represent approximately 30,769,230 Ordinary Shares, amounting to 6.8% of the current issued share capital of the Company. However, as the average Byotrol share price since the issue of the Convertible Bond has been below the 3.25p conversion price, these are currently classed as non-dilutive and do not feature in the Denominator calculation above. |
Posted at 05/4/2024 15:11 by mudbath Well as the Byotrol share price has been manoeuvred downwards to almost zero I would suggest that there is considerable value to be had through investing at around 0.09p; for little has changed since the share price was ten or more times higher.I would not be surprised to see corporate action prior to the General Meeting. |
Posted at 04/4/2024 14:10 by kumbuka mudbath12 Jan '13 - 10:06 - 7 of 12704 0 0 0 The covering analyst at Finncap,Dr.Keith Redpath,suggests that Byotrol might lose £700k over the full year to Mar 31st 2013.This would indicate a loss of just £23k for the current six months. If correct,the losses for the past 3 six monthly trading periods would read:- March 2012= £1377k Sept 2012= £677k March 2013= £23k An impressive trend then,which if maintained, could see BYOT report profits of over £500k for the six months to Sept 2013;although Byotrol house brokers are forecasting a more modest 300k profit for the full year. Reading between the lines,BYOT are looking at a surge in orders.Why else would they be seeking to put in place a significant invoice discounting facility with their bankers. With an IDF in place,Finncap predict BYOT could turn cash flow neutral within the current trading period,possibly then precluding the need for a further large cash raising exercise After several disappointing years,Byotrol seems to be coming good at quite a pace,and imo this pace could quicken Finncap have in place an initial share price target of 15 pence. The share price chart currently looks strong and it could be that such a level is soon tested. A very interesting investment opportunity. |
Posted at 02/4/2024 14:34 by tradertrev Personally I think management have shown that they are no longer interested in the wider shareholder base and have fallen into the classic smallcap trap of thinking that the current shareholders are somehow to blame for the appalling share price performance, not realising that it is the ex-shareholders who sold the shares that brought the share price down.It is the long-suffering long term holders who have been punished by the lack of any good news from the company, which is now being compounded my management turning their backs on us. If management of an AIM company is not on our side, then in my view there is no basis to hold the shares, so I dumped nearly all my shares last week at 0.1p except for one tiny account where the proceeds wouldn't have paid the contract fee! Fortunately this was never a big holding for me - I think I bought them back in the Noughties! I wish continuing shareholders better fortune going forward. TT |
Posted at 31/3/2024 20:55 by sikhthetech Warnings about marketing/supply chains and the time for a placing was when it was obvious covid was a pandemic.sikhthetech - 26 Oct 2021 - 18:57:43 - 8940 of 10283 1gw, You're clueless, as usual...read the company newsflow... The time for a placing was last year, March-April, in the middle of the 1st lockdown. Byot knew in March sales rose significantly. March, there was a lockdown and by April it was clear there was a pandemic. So I think a placing March-April would have been well received by IIs and PIs, as was the case with many other companies. The share price end of March was around 5p, so around current share price <...> April 2020: "We continue to experience exceptional demand for our technologies across all our markets due to the covid19 pandemic. We expect this to continue for at least the first quarter of FY2021 and likely beyond, and are now expecting to benefit significantly from a secular shift towards the heightened importance of infection prevention, cleanliness and hygiene, whether personal, institutional or environmental." It isn't hindsight either as you wrongly claim, on 17th March 2020, I posted the following. What part of the highlighted sentence don't you understand? sikhthetech - 17 Mar 2020 - 20:12:36 - 4993 of 8940 The problem isn't it's effectiveness, it's their supply chain, their marketing. <...> |
Posted at 20/3/2024 12:41 by kumbuka BYOTmudbath 12 Jan '13 - 10:06 - 7 of 12570 0 0 0 The covering analyst at Finncap,Dr.Keith Redpath,suggests that Byotrol might lose £700k over the full year to Mar 31st 2013.This would indicate a loss of just £23k for the current six months. If correct,the losses for the past 3 six monthly trading periods would read:- March 2012= £1377k Sept 2012= £677k March 2013= £23k An impressive trend then,which if maintained, could see BYOT report profits of over £500k for the six months to Sept 2013;although Byotrol house brokers are forecasting a more modest 300k profit for the full year. Reading between the lines,BYOT are looking at a surge in orders.Why else would they be seeking to put in place a significant invoice discounting facility with their bankers. With an IDF in place,Finncap predict BYOT could turn cash flow neutral within the current trading period,possibly then precluding the need for a further large cash raising exercise After several disappointing years,Byotrol seems to be coming good at quite a pace,and imo this pace could quicken Finncap have in place an initial share price target of 15 pence. The share price chart currently looks strong and it could be that such a level is soon tested. A very interesting investment opportunity. |
Posted at 20/3/2024 11:58 by mudbath I wonder what it is "coming down the tracks" sufficient to derail the BYOT share price to such an extent.My leaning is towards the announcement strategic review; although a futher BoD resignation, a delisting or a placing could be alternative scenarios. Byotrol carries way too many staff whose purpose is unclear. We should soon find out. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
